Daniel originally joined Kaiser Permanente Ventures in 2017. He brings over 18 years of expertise across healthcare venture capital, venture-backed business operations, and investment banking. He is based in the San Francisco Bay Area.

His investment work at KPV spans the healthcare technology and services landscape and includes NOCD, Ordr, Nuvolo (acquired), NextHealth (acquired), Vesta Healthcare, Talix (acquired), Collective Medical (acquired), and Protenus. He also supported follow-on and exit processes for Leiter’s (acquired), Ginger (merged), and Health Catalyst (IPO).

Daniel also led the US Digital Health practice at Endeavour Vision, a transatlantic venture capital firm, as a Senior Investment Director. Previously, Daniel was the Director of Strategy & Operations at Lumiata, a clinical analytics platform that predicts disease risk (acquired by Somatus). Earlier in his career, Daniel worked at Safeguard Scientifics, a healthcare and technology venture capital firm where he performed investment analyses in healthcare IT, specialty pharmaceuticals, diagnostics, and medical devices. Daniel began his career in healthcare investment banking where he focused on cross-border transactions in the US, Europe, and the Middle East at Citigroup and EC Mergers & Acquisitions.

Daniel holds an MBA in Healthcare Management from The Wharton School and a BS in Biological Engineering from Cornell University.